Or. Admin. Code § 855-080-0021 - Schedule I
(1) Schedule I
consists of the drugs and other substances, by whatever official, common,
usual, chemical, or brand name designated, listed in
21 CFR
1308.11 (04/01/2023), and unless specifically
exempt or unless listed in another schedule, any quantity of the following
substances, including their isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers, whenever the existence of such isomers, esters,
ethers, and salts is possible within the specific chemical designation:
(a) 1,4-butanediol;
(b) Gamma-butyrolactone
(c) Methamphetamine, except as listed in OAR
855-080-0022;
(d)
Dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide (U-47700)
(e)
4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]piperidin-2-ylidene]benzenesulfonamide
(W-18) and positional isomers thereof, and any substituted derivative of W-18
and its positional isomers, and their salts, by any substitution on the
piperidine ring (including replacement of all or part of the nitrophenylethyl
group), any substitution on or replacement of the sulfonamide, or any
combination of the above that are not FDA approved drugs, unless specifically
excepted or when in the possession of an FDA registered manufacturer or a
registered research facility, or a person for the purpose of sale to an FDA
registered manufacturer or a registered research facility.
(f) Substituted derivatives of cathinone and
methcathinone that are not listed in OARs
855-080-0022 through 0026
(Schedules II through V) or are not FDA approved drugs, including but not
limited to,
(A) Methylmethcathinone
(Mephedrone);
(B)
Methylenedioxypyrovalerone (MDPV);
(C) Methylenedioxymethylcathinone
(Methylone);
(D)
2-Methylamino-3',4'-(methylenedioxy)-butyrophenone (Butylone);
(E) Fluoromethcathinone
(Flephedrone);
(F)
4-Methoxymethcathinone (Methedrone).
(2) Schedule I also includes any compounds in
the following structural classes (2a-2k) and their salts, that are not FDA
approved drugs, unless specifically excepted or when in the possession of an
FDA registered manufacturer or a registered research facility, or a person for
the purpose of sale to an FDA registered manufacturer or a registered research
facility:
(a) Naphthoylindoles: Any compound
containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen
atom of the indole ring whether or not further substituted in the indole ring
to any extent and whether or not substituted in the naphthyl ring to any
extent. Examples of this structural class include but are not limited to:
JWH-015, JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210,
AM-1220, MAM-2201 and AM-2201;
(b)
Phenylacetylindoles: Any compound containing a 3-phenylacetylindole structure
with substitution at the nitrogen atom of the indole ring whether or not
further substituted in the indole ring to any extent, whether or not
substituted in the phenyl ring to any extent. Examples of this structural class
include but are not limited to: JWH-167, JWH -201, JWH-203, JWH-250, JWH-251,
JWH-302 and RCS-8;
(c)
Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure with
substitution at the nitrogen atom of the indole ring whether or not further
substituted in the indole ring to any extent and whether or not substituted in
the phenyl ring to any extent. Examples of this structural class include but
are not limited to: RCS-4, AM-694, AM-1241, and AM-2233;
(d) Cyclohexylphenols: Any compound
containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the
5-position of the phenolic ring whether or not substituted in the cyclohexyl
ring to any extent. Examples of this structural class include but are not
limited to: CP 47,497 and its C8 homologue (cannabicyclohexanol);
(e) Naphthylmethylindoles: Any compound
containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at
the nitrogen atom of the indole ring whether or not further substituted in the
indole ring to any extent and whether or not substituted in the naphthyl ring
to any extent;
(f)
Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole structure
with substitution at the nitrogen atom of the pyrrole ring whether or not
further substituted in the pyrrole ring to any extent and whether or not
substituted in the naphthyl ring to any extent;
(g) Naphthylmethylindenes: Any compound
containing a 1-(1-naphthylmethyl) indene structure with substitution at the
3-position of the indene ring whether or not further substituted in the indene
ring to any extent and whether or not substituted in the naphthyl ring to any
extent;
(h) Cyclopropanoylindoles:
Any compound containing an 3-(cyclopropylmethanoyl)indole structure with
substitution at the nitrogen atom of the indole ring, whether or not further
substituted in the indole ring to any extent and whether or not substituted in
the cyclopropyl ring to any extent. Examples of this structural class include
but are not limited to: UR-144, XLR-11 and A-796,260;
(i) Adamantoylindoles: Any compound
containing a 3-(1-adamantoyl)indole structure with substitution at the nitrogen
atom of the indole ring, whether or not further substituted in the indole ring
to any extent and whether or not substituted in the adamantyl ring to any
extent. Examples of this structural class include but are not limited to:
AM-1248 and AB-001;
(j)
Adamantylindolecarboxamides: Any compound containing an
N-adamantyl-1-indole-3-carboxamide with substitution at the nitrogen atom of
the indole ring, whether or not further substituted in the indole ring to any
extent and whether or not substituted in the adamantyl ring to any extent.
Examples of this structural class include but are not limited to: STS-135 and
2NE1; and
(k)
Adamantylindazolecarboxamides: Any compound containing an
N-adamantyl-1-indazole-3-carboxamide with substitution at the nitrogen atom of
the indazole ring, whether or not further substituted in the indazole ring to
any extent and whether or not substituted in the adamantyl ring to any extent.
Examples of this structural class include but are not limited to:
AKB48.
(3) Schedule I
also includes any other cannabinoid receptor agonist that is not listed in OARs
855-080-0022 through 0026
(Schedules II through V) is not an FDA approved drug or is exempted from the
definition of controlled substance in ORS
475.005(6)(b)(A)-(E).
(4) Schedule I also includes any substituted
derivatives of fentanyl that are not listed in OARs
855-080-0022 through 0026
(Schedules II through V) or are not FDA approved drugs, and are derived from
fentanyl by any substitution on or replacement of the phenethyl group, any
substitution on the piperidine ring, any substitution on or replacement of the
propanamide group, any substitution on the phenyl group, or any combination of
the above.
(5) Schedule I also
includes any compounds in the following structural classes (a - b), and their
salts, that are not listed in OARs
855-080-0022 through 0026
(Schedules II through V) or FDA approved drugs, unless specifically excepted or
when in the possession of an FDA registered manufacturer or a registered
research facility, or a person for the purpose of sale to an FDA registered
manufacturer or a registered research facility:
(a) Benzodiazepine class: A fused
1,4-diazepine and benzene ring structure with a phenyl connected to the
diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine
or benzene ring, any substitution(s) on the phenyl ring, or any combination
thereof. Examples of this structural class include but are not limited to:
Clonazolam, Flualprazolam
(b)
Thienodiazepine class: A fused 1,4-diazepine and thiophene ring structure with
a phenyl connected to the 1,-4-diazepine ring, with any substitution(s) or
replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on
the phenyl ring, or any combination thereof. Examples of this structural class
include but are not limited to: Etizolam
(6) Exceptions. The following are exceptions
to subsection (1) of this rule:
(a) 1,
4-butanediol and gamma-butyrolactone when in the possession of a person for the
purpose of its sale to a legitimate manufacturer of industrial products and the
person is in compliance with the Drug Enforcement Administration requirements
for List I Chemicals;
(b) 1,
4-butanediol and gamma-butyrolactone when in the possession of a person for the
purpose of the legitimate manufacture of industrial products;
(c) The following substances per ORS
475.005(6)(b):
(A) The plant Cannabis family
Cannabaceae;
(B) Any part of the
plant Cannabis family Cannabaceae, whether growing or not;
(C) Resin extracted from any part of the
plant Cannabis family Cannabaceae;
(D) The seeds of the plant Cannabis family
Cannabaceae; or
(E) Any compound,
manufacture, salt, derivative, mixture or preparation of a plant, part of a
plant, resin or seed described in this paragraph.
Notes
Publications: Publications referenced are available for review at the agency.
Statutory/Other Authority: ORS 689.205
Statutes/Other Implemented: ORS 475.005, ORS 475.035, ORS 475.055 & ORS 475.065
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.